上皮性卵巢癌化疗增敏的表观遗传学治疗。
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
机构信息
Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
出版信息
Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.
Abstract
Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.
摘要
表观遗传学药物已被证明可以增强卵巢癌细胞系和动物模型中的基因表达和药物敏感性。基于有前景的临床前研究，DNA 甲基化抑制剂与现有的化疗药物联合使用有可能克服获得性耐药性，为这一特定类别的表观遗传学药物在卵巢癌临床试验中奠定了基础。最近完成的地西他滨 I 期临床试验为评估患者反应的剂量方案和生物学终点提供了重要信息。此外，表观遗传学药物对药效学靶点的影响开始显现，预测性表观遗传生物标志物和下一代表观基因组治疗药物正在开发中，以便在卵巢癌患者的临床环境中应用。
相似文献
1
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.
2
Epigenomics and ovarian carcinoma.
Biomark Med. 2010 Aug;4(4):543-70. doi: 10.2217/bmm.10.72.
3
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Ann Med. 2015;47(5):359-69. doi: 10.3109/07853890.2015.1043140. Epub 2015 Jul 10.
4
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
Eur J Pharmacol. 2022 Jul 15;927:175071. doi: 10.1016/j.ejphar.2022.175071. Epub 2022 May 27.
5
Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Clin Epigenetics. 2021 Aug 28;13(1):167. doi: 10.1186/s13148-021-01149-8.
6
Epigenetic therapy for ovarian cancer: promise and progress.
Clin Epigenetics. 2019 Jan 15;11(1):7. doi: 10.1186/s13148-018-0602-0.
7
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Genome Med. 2016 Oct 20;8(1):107. doi: 10.1186/s13073-016-0361-5.
8
Epigenetics in ovarian cancer.
Methods Mol Biol. 2012;863:253-69. doi: 10.1007/978-1-61779-612-8_15.
9
Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Clin Breast Cancer. 2018 Jun;18(3):189-191. doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19.
10
Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a -Dependent Manner.
Cancer Res. 2021 Oct 15;81(20):5176-5189. doi: 10.1158/0008-5472.CAN-20-4243. Epub 2021 Aug 25.
引用本文的文献
1
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations.
Int J Mol Sci. 2024 Aug 26;25(17):9241. doi: 10.3390/ijms25179241.
2
Sex difference in human diseases: mechanistic insights and clinical implications.
Signal Transduct Target Ther. 2024 Sep 10;9(1):238. doi: 10.1038/s41392-024-01929-7.
3
The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome.
Biomolecules. 2023 Jul 1;13(7):1066. doi: 10.3390/biom13071066.
4
The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.
Genes (Basel). 2022 Aug 29;13(9):1555. doi: 10.3390/genes13091555.
5
Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time.
Biomolecules. 2021 Nov 17;11(11):1711. doi: 10.3390/biom11111711.
6
Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis.
Cancers (Basel). 2021 Sep 24;13(19):4795. doi: 10.3390/cancers13194795.
7
Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents.
Oncol Lett. 2019 Sep;18(3):2404-2411. doi: 10.3892/ol.2019.10564. Epub 2019 Jul 4.
8
Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome.
Front Oncol. 2019 Apr 5;9:246. doi: 10.3389/fonc.2019.00246. eCollection 2019.
9
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
Cancer Res. 2018 Oct 15;78(20):5754-5766. doi: 10.1158/0008-5472.CAN-17-3953. Epub 2018 Sep 5.
10
A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.
PLoS One. 2018 Jun 21;13(6):e0199130. doi: 10.1371/journal.pone.0199130. eCollection 2018.
本文引用的文献
1
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Cancer. 2010 Sep 1;116(17):4043-53. doi: 10.1002/cncr.25204.
2
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.
BMC Med Genomics. 2009 Jun 8;2:34. doi: 10.1186/1755-8794-2-34.
3
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Neoplasia. 2009 Jun;11(6):552-63, 3 p following 563. doi: 10.1593/neo.09204.
4
The biology of ovarian cancer: new opportunities for translation.
Nat Rev Cancer. 2009 Jun;9(6):415-28. doi: 10.1038/nrc2644.
5
CpG islands--'a rough guide'.
FEBS Lett. 2009 Jun 5;583(11):1713-20. doi: 10.1016/j.febslet.2009.04.012. Epub 2009 Apr 18.
6
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Fam Cancer. 2009;8(4):339-46. doi: 10.1007/s10689-009-9240-1. Epub 2009 Apr 2.
7
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Br J Cancer. 2009 Mar 10;100(5):758-63. doi: 10.1038/sj.bjc.6604932.
8
Beyond chemotherapy: targeted therapies in ovarian cancer.
Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583.
9
The promises and pitfalls of epigenetic therapies in solid tumours.
Eur J Cancer. 2009 May;45(7):1129-1136. doi: 10.1016/j.ejca.2009.01.003. Epub 2009 Feb 11.
10
Aberrant promoter methylation of SPARC in ovarian cancer.
Neoplasia. 2009 Feb;11(2):126-35. doi: 10.1593/neo.81146.
Zotero 插件